HER2 treatment in colorectal cancer – pro
Emerging evidence suggests a small subset of late-stage colon cancer driven by HER2, a biomarker routinely evaluated in select breast and gastric cancers, may respond to HER2-targeted therapy. Such patients maybe identified thotugh using panels of molecular markers. One such study that used My Pathway panel found that interim data show that HER2-targeted therapy with pertuzumab + trastuzumab, a chemotherapy-free regimen, is active in heavily pretreated HER2-amplified/overexpressed mCRC. The ORR was 37.5%, responses were durable (median 11.1 months), and the CBR was 46.9%. However, this study is still ongoing and it is acknowledged that this approach remains experimental at this time because it requires more study.
W Larry Glucket al, Prolonged response of widely metastatic HER2-positive colon cancer to trastuzumab therapy, https://www.futuremedicine.com/doi/full/10.2217/crc-2017-0006 2017
erbert Hurwitz, Kanwal Pratap Singh Raghav, Howard A. Burris, Razelle Kurzrock, Christopher Sweeney, Funda Meric-Bernstam, Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Journal of Clinical Oncology 2017 35:4_suppl, 676-676
NCCN Rectal Cancer 2018